Analgesic-associated nephropathy and transitional cell carcinoma of the urinary tract.
Epidemiologic studies from Europe suggest that patients with analgesic-associated nephropathy have an increased risk of developing transitional cell carcinoma of the urinary tract. We did a similar epidemiologic study supporting this association. Six of 115 cases of transitional cell carcinoma diagnosed over 3 years had analgesic-associated nephropathy. The patients were predominantly female, younger, and had renal pelvis tumors instead of bladder tumors (P < 0.002), an mortality rate was higher (P < 0.05). In a historical prospective study, 146 patients with interstitial nephritis diagnosed between 1974 and 1976 were divided into those with and those without analgesic-associated nephropathy. In 4 of 84 patients with analgesic-associated nephropathy transitional cell carcinoma has developed. None of the 98 patients without analgesic associated nephropathy have developed transitional cell carcinoma (P < 0.001). These data strongly incriminate analgesic abuse as a risk factor for the development of transitional cell carcinoma.
D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D007676:Kidney Failure, Chronic / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000139:chemically induced; D010615:Phenacetin / Q000009:adverse effects*; D011446:Prospective Studies; D012189:Retrospective Studies; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000453:epidemiology
D010615:Phenacetin